Track topics on Twitter Track topics that are important to you
A collaboration between Integrated BioTherapeutics (IBT) and The Scripps Research Institute (TSRI) has been awarded a $6.6 million, 5-year grant by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine that protects against all ebolaviruses. "This award will enable us to address a pressing global public health need, namely a single vaccine that can protect against all ebolaviruses,” stated IBT’s CSO, M. Javad Aman, Ph.D., who is co-principal investigator for the collaboration. “To meet this challenge, we have assembled a unique team of experts in immunogen design, structural biology, vaccine development, and animal models of filovirus infection.” Filoviruses, including Ebolavirus , Sudan ebolavirus , Bundibugyo ebolavirus , and Marburg marburgvirus , cause hemorrhagic fever in humans, and infection is lethal in 40% to 90% of cases. The most recent Ebolavirus outbreak in West Africa was caused by the ...
Original Article: IBT, Scripps Win $6.6M to Develop Pan-Ebolavirus VaccineNEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...